For example, c-jun+ Her2 targeted CAR T cells showed improved survival for 143B osteosarcoma tumor growth in vivo and strong in vivo expansion of these CAR T cells compared to control counterpart Her2 CAR T cells. This evidence concerns the gene ERBB2 and osteosarcoma.